Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Clinical trial NCT04636008 · RECRUITING

Trial details

NCT number: NCT04636008
Sponsor: West China Hospital
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Anti-PD-1 Antibody Radiotherapy Rectal Cancer MSI-H Mmr Deficiency

Start date: 2020-08-14
Primary completion: 2024-12-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.